UroGen Pharma appoints Daniel G. Wildman to board of directors

UroGen Pharma Ltd.

Daniel G. Wildman appointed to fill a board vacancy effective November 8, 2022.
Initial option grant of 20,000 ordinary shares, vesting in equal quarterly installments over 12 quarters.
Annual retainer of $40,000 for board service plus $5,000 for service on the Compliance Committee.
Eligible for annual option grant of 10,000 ordinary shares at each annual shareholder meeting.

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Daniel G. Wildman

Director

URGN · UroGen Pharma Ltd.

Effective: 2022-11-08
Filed: November 9, 2022, 6:59 PM ET

On November 8, 2022, Daniel G. Wildman was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Daniel G. Wildman was appointed as Director at UroGen Pharma Ltd..

Action: appointed
Role: Director

Exact text from the filing

On November 8, 2022, Daniel G. Wildman was appointed to the board of directors (the “Board”) of UroGen Pharma Ltd., an Israeli company (the “Company”), to fill a vacancy on the Board and to hold office until the Company’s 2023 Annual Meeting of Shareholders

View on SEC.gov

UroGen Pharma Ltd. filing history →

Source: SEC EDGAR

accession 0001193125-22-280620

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.